Piramal Pharma Gains 18% Q2 Revenue Jump of 28% | CNBC TV18
CNBC-TV18 · 28 Oct 2026 · 6 min
Management interview of Piramal Pharma Ltd (PPLPHARMA), with 5 key numbers discussed.
- Nandini Piramal, Chairperson, Piramal Pharma
Piramal Pharma has increased its revenue guidance to 19-20% for the year, supported by broad-based momentum across all three operating segments. Management expects significant improvement in EBITDA and PAT margins through operational leverage, as fixed costs remain largely steady. In Q2, the company added 22 new customers, primarily US biotech clients in the CDMO business. The phase three pipeline holds 28 molecules that could commercialise over the next one to three years. The net debt to EBITDA ratio continues to decline as EBITDA improves.